Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 5/5 | 5/5 |
| User rating | 4.5 (168) | 4.5 (58) |
| Typical dose | Topical form: 1 ml of 5% solution or the equivalent foam dose, applied twice daily to dry scalp (women sometimes use 5% foam once daily or a 2% solution). Oral form (LDOM, off-label): typically 0.625-5 mg/day, most often 1.25-2.5 mg, individually dosed by a physician | Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal |
| Form | Topical solution or foam; tablets split for the oral form (compounding pharmacy preparation) | Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound) |
| Average price | 35-90 zł za opakowanie formy miejscowej starczające na miesiąc stosowania (cena zależy od koncentracji, formy i producenta — generyki są tańsze niż marki oryginalne) | ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki |
| Monthly cost | ok. 35-90 zł/miesiąc dla formy miejscowej; forma doustna (receptura) zwykle wychodzi wyraźnie taniej, ale wymaga recepty i wizyty lekarskiej | ok. 1000–1600 zł/miesiąc |
| Time to effects | The temporary shedding phase can appear as early as weeks 2-8 of treatment. The first visible signs of regrowth usually appear after 3-4 months of consistent use, with a fully assessable clinical effect after 6-12 months of uninterrupted treatment. The effect requires indefinite continuation; it fades within a few months of stopping. | Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment. |
| Who it's for | Men with early- to moderate-stage androgenetic alopecia, especially in the crown area (less effective where follicles are already completely lost in advanced frontal balding) | People with type 2 diabetes with inadequate glycemic control on other oral medications |